Stockscreener 앱 받기
9.72
2.70%
-0.27
시간 외 거래:
9.72
전일 마감가:
$9.99
열려 있는:
$9.74
하루 거래량:
401.51K
Relative Volume:
0.42
시가총액:
$741.05M
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-3.3633
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
+1.67%
1개월 성능:
-16.28%
6개월 성능:
-55.92%
1년 성능:
-35.93%
1일 변동 폭
$9.545
$9.86
1주일 범위
$9.25
$10.14
52주 변동 폭
$8.18
$29.56
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
NRIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
9.72 | 728.81M | 54.55M | -193.57M | -181.86M | -2.89 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Point72 Asset Management L.P. Buys Shares of 872,959 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
D. E. Shaw & Co. Inc. Acquires 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Deutsche Bank AG Sells 323,485 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Soleus Capital Management L.P. Has $39.62 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
97,889 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by Velan Capital Investment Management LP - MarketBeat
Vestal Point Capital LP Purchases 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Northern Trust Corp Grows Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Jacobs Levy Equity Management Inc. Buys Shares of 229,369 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Nurix Therapeutics reports stockholder voting results - Investing.com
Ensign Peak Advisors Inc Acquires 194,673 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) is Patient Square Capital LP's 6th Largest Position - MarketBeat
Parkman Healthcare Partners LLC Has $10.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Cubist Systematic Strategies LLC Acquires Shares of 124,025 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Integral Health Asset Management LLC - MarketBeat
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listin - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference - TradingView
Nurix Therapeutics Announces Presentations of Clinical Data at t - GuruFocus
Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma - The Manila Times
Nurix Therapeutics to Present Phase 1a/b Clinical Trial Data on Bexobrutideg (NX-5948) for CLL and Waldenström Macroglobulinemia at EHA 2025 and 18-ICML Conferences - Nasdaq
Breakthrough Blood Cancer Treatment: Nurix's BTK Degrader Shows Promising Clinical Results in CLL Patients - Stock Titan
Where are the Opportunities in (NRIX) - news.stocktradersdaily.com
Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
10 Best Low Priced Biotech Stocks to Buy Now - Insider Monkey
Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being - simplywall.st
Voya Investment Management LLC Acquires 34,811 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
135,903 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Purchased by First Trust Advisors LP - MarketBeat
Raymond James Financial Inc. Takes $1.03 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Deep Track Capital LP Sells 868,104 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Invesco Ltd. Decreases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Boxer Capital Management LLC Makes New Investment in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by JPMorgan Chase & Co. - MarketBeat
RA Capital Management L.P. Acquires Shares of 1,333,333 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Price T Rowe Associates Inc. MD - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Nurix Therapeutics (NASDAQ:NRIX) - MarketBeat
Darwin Global Management Ltd. Invests $3.08 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Schonfeld Strategic Advisors LLC Boosts Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Lord Abbett & CO. LLC Boosts Stake in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
(NRIX) Trading Signals - news.stocktradersdaily.com
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
17.27%
1.06%
자본화:
|
볼륨(24시간):